[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100452756":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":31,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":20,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":20,"overallStatus":59,"whyStopped":20,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":20},{"fullName":5,"class":6},"Scripps Translational Science Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Subjects identified by Optum Health","EXPERIMENTAL","10,000 individuals identified by Optum Health as likely meeting inclusion criteria by claims analysis.",[13],"Behavioral: Genetic risk assessment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","Genetic risk assessment","A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Ali Torkamani, PhD","CONTACT","858-784-2082","atorkama@scripps.edu",{"type":28,"investigatorFullName":29,"investigatorTitle":30,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Ali Torkamani","Director of Genomics and Genome Informatics",[32,35,37],{"name":33,"class":34},"Illumina, Inc.","INDUSTRY",{"name":36,"class":34},"Optum, Inc.",{"name":38,"class":34},"Quest Diagnostics-Nichols Insitute","100452756","prospective-electronic-polygenic-risk-study---second-phase-100452756",false,"NCT05175651","Prospective Electronic Polygenic Risk Study - Second Phase","PEPRS2","Inclusion Criteria:\n\n* 45 ≥ Age \\\u003C 65\n* ASCVD Risk Score \\> 7.5% as defined by the standard pooled cohort equation\n* Access to and ability to use a smartphone\n\nExclusion Criteria:\n\n* Prior diagnosis of coronary disease as defined by prior myocardial infarction (STEMI or NSTEMI), or revascularization (stent or coronary artery bypass grafting)\n* Prior diagnosis or treatment of glaucoma\n* Cerebrovascular disease with history of ischemic stroke, TIA, carotid endarterectomy, carotid artery stenting\n* Peripheral arterial disease with history of claudication, revascularization (stents or bypass)\n* Current and active high-intensity statin prescription (rosuvastatin 20 mg, rosuvastatin 40 mg, atorvastatin 40 mg and atorvastatin 80 mg)\n* Anti-PCSK9 therapy\n* Lipid apheresis therapy\n* Currently enrolled in a clinical trial for lipid lowering therapy\n* Known statin intolerance to 2 or more statins in the past","ALL","45 Years","65 Years",{"count":50,"type":51},10000,"ESTIMATED","INTERVENTIONAL",[54],"NA","This study will investigate the role of polygenic risk scores (PRS) in preventive health.",[57,58],"Coronary Artery Disease","Glaucoma","NOT_YET_RECRUITING","2022-11-03",{"date":62,"type":63},"2022-11-07","ACTUAL",{"date":65,"type":51},"2023-06",{"date":67,"type":51},"2027-01-15",{"name":5,"class":6}]